CIA
NTLA icon

Capital Impact Advisors’s Intellia Therapeutics NTLA Stock Holding History

Capital Impact Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-26,554
Closed -$594K – 29
2024
Q2 		$594K Sell
26,554
-5,439
-17% -$130K 1.67% 38
2024
Q1 		$880K Buy
31,993
+5,865
+22% +$163K 1.14% 35
2023
Q4 		$797K Buy
26,128
+14,750
+130% +$424K 1.05% 47
2023
Q3 		$360K Hold
11,378
– – 0.6% 74
2023
Q2 		$464K Buy
11,378
+673
+6% +$27.3K 0.51% 97
2023
Q1 		$399K Hold
10,705
– – 0.49% 93
2022
Q4 		$373K Sell
10,705
-1,249
-10% -$59.4K 0.36% 119
2022
Q3 		$586K Buy
11,954
+464
+4% +$28.8K 0.58% 52
2022
Q2 		$595K Buy
11,490
+3,290
+40% +$167K 0.55% 69
2022
Q1 		$596K Buy
8,200
+3,338
+69% +$283K 0.43% 116
2021
Q4 		$575K Sell
4,862
-2,638
-35% -$330K 0.4% 77
2021
Q3 		$1.01M Buy
+7,500
New +$1.14M 0.4% 100
2021
Q2 		– Sell
-4,468
Closed -$359K – 134
2021
Q1 		$359K Sell
4,468
-215,532
-98% -$14.5M 0.13% 102
2020
Q4 		$12M Buy
220,000
+110,000
+100% +$3.99M 2.94% 2
2020
Q3 		$2.19M Buy
+110,000
New +$2.29M 0.65% 72

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Impact Advisors's NTLA Position: Q3 2024 in Review

Capital Impact Advisors sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 26,554 shares — an estimated $594K sold.

Capital Impact Advisors first reported a position in NTLA in Q3 2020 and held it in 15 quarters. The position peaked at $12M in Q4 2020. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

  • Capital Impact Advisors reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Capital Impact Advisors sold 26,554 Intellia Therapeutics shares in Q3 2024, an estimated $594K.
  • Capital Impact Advisors first reported a position in Intellia Therapeutics in Q3 2020 and held it in 15 quarters.
  • Capital Impact Advisors's Intellia Therapeutics position peaked at $12M in Q4 2020.
  • 283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Capital Impact Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.